|
|
|
|
| LEADER |
01000cam a2200265 4500 |
| 001 |
1667287435 |
| 003 |
DE-627 |
| 005 |
20230905070940.0 |
| 007 |
tu |
| 008 |
190612s2019 xx ||||| 00| ||eng c |
| 020 |
|
|
|a 9781788013949
|9 978-1-78801-394-9
|
| 024 |
3 |
|
|a 9781788013949
|
| 035 |
|
|
|a (DE-627)1667287435
|
| 035 |
|
|
|a (DE-599)KXP1667287435
|
| 035 |
|
|
|a (OCoLC)1108338272
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rda
|
| 041 |
|
|
|a eng
|
| 084 |
|
|
|a WD 5355
|2 rvk
|0 (DE-625)rvk/148201:
|
| 084 |
|
|
|a 44.47
|2 bkl
|
| 084 |
|
|
|a 44.38
|2 bkl
|
| 245 |
1 |
0 |
|a MicroRNAs in diseases and disorders
|b emerging therapeutic targets
|c edited by Philip V. Peplow (University of Otago, New Zealand), Bridget Martinez (Los Alamos National Laboratory, USA), George A. Calin (MD Anderson Cancer Center, USA) and Aurora Esquela-Kerscher (Eastern Virginia Medical School)
|
| 264 |
|
1 |
|a London
|b Royal Society of Chemistry
|c [2019]
|
| 300 |
|
|
|a xx, 480 Seiten
|b Illustrationen
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 490 |
1 |
|
|a Drug discovery series
|v 69
|
| 689 |
0 |
0 |
|D s
|0 (DE-588)7736808-3
|0 (DE-627)647719754
|0 (DE-576)33804700X
|a miRNS
|2 gnd
|
| 689 |
0 |
1 |
|D s
|0 (DE-588)1028794711
|0 (DE-627)731606108
|0 (DE-576)376264608
|a Zielstruktur
|2 gnd
|
| 689 |
0 |
|
|5 (DE-627)
|
| 700 |
1 |
|
|a Peplow, Philip V.
|e herausgeberin
|4 edt
|
| 700 |
1 |
|
|a Martinez, Bridget
|e herausgeberin
|4 edt
|
| 700 |
1 |
|
|a Calin, George A.
|e herausgeberin
|4 edt
|
| 700 |
1 |
|
|a Esquela-Kerscher, Aurora
|e herausgeberin
|4 edt
|
| 776 |
1 |
|
|z 9781788016421
|c PDF
|
| 776 |
1 |
|
|z 9781788017817
|c EPUB
|
| 830 |
|
0 |
|a RSC drug discovery series
|v 69
|9 69
|w (DE-627)633134899
|w (DE-576)330758381
|w (DE-600)2569164-8
|x 2041-3203
|7 ns
|
| 856 |
4 |
2 |
|u https://www.gbv.de/dms/bs/toc/1667287435.pdf
|m V:DE-601
|m B:DE-84
|q pdf/application
|3 Inhaltsverzeichnis
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a ISIL_DE-84
|
| 912 |
|
|
|a SYSFLAG_1
|
| 912 |
|
|
|a GBV_KXP
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a SSG-OPC-PHA
|
| 912 |
|
|
|a SSG-OPC-DE-84
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a ISIL_DE-3
|
| 912 |
|
|
|a GBV_ILN_65_a150
|
| 912 |
|
|
|a GBV_ILN_2007
|
| 912 |
|
|
|a ISIL_DE-352
|
| 912 |
|
|
|a GBV_ILN_2011
|
| 912 |
|
|
|a ISIL_DE-16
|
| 936 |
r |
v |
|a WD 5355
|b RNA
|k Biologie
|k Biophysik, Biochemie, Physiologische Chemie
|k Spezielle Biochemie und Biophysik
|k Biochemie und Biophysik organischer Verbindungen
|k Biologisch inaktive Proteine und Proteide insgesamt, auch: Proteinfaltung, Proteinbiosynthese
|k Nucleinsäuren, Nucleoproteine
|k RNA
|0 (DE-627)1271477343
|0 (DE-625)rvk/148201:
|0 (DE-576)201477343
|
| 936 |
b |
k |
|a 44.47
|j Pathologie
|x Medizin
|0 (DE-627)106409301
|
| 936 |
b |
k |
|a 44.38
|j Pharmakologie
|0 (DE-627)106409743
|
| 951 |
|
|
|a BO
|
| 980 |
|
|
|2 20
|1 01
|x 0084
|b 3616937809
|c 00
|f MAG
|d 2962-0225
|e --%%--
|j --%%--
|y k
|z 04-06-20
|
| 980 |
|
|
|2 65
|1 01
|x 3/150
|b 3506185519
|c 00
|f Ha 150
|d VS 5350 101
|e u
|j --%%--
|y za150
|z 09-08-19
|
| 980 |
|
|
|2 2007
|1 01
|x DE-352
|b 3486205854
|c 00
|f --%%--
|d --%%--
|e --%%--
|j --%%--
|y l01
|z 12-06-19
|
| 980 |
|
|
|2 2011
|1 01
|x DE-16
|b 3511549450
|c 00
|f --%%--
|d UBN/WD 5355 P422
|e --%%--
|j --%%--
|y l01
|z 04-09-19
|
| 984 |
|
|
|2 20
|1 01
|x 0084
|a 84$103544764
|
| 984 |
|
|
|2 65
|1 01
|x 3/150
|a 3/150$00374628
|
| 984 |
|
|
|2 2011
|1 01
|x DE-16
|a 105954682
|
| 985 |
|
|
|2 65
|1 01
|x 3/150
|a 150/2019/00472
|
